Difference between revisions of "Londahl"
(Imported from Wikispaces) |
|||
| Line 1: | Line 1: | ||
| − | |||
| − | + | <span style="font-size:x-large;">'''<span style="font-family: 'Arial','sans-serif';">The addition of hyperbaric oxygenation to a specialised wound care program for chronic diabetic foot ulcers resulted in improved survival, healing and quality of life.</span>'''</span> | |
| − | + | ||
| − | + | '''<span style="font-family: 'Arial','sans-serif'; font-size: 16px;">Clinical bottom line:</span>''' | |
| + | |||
| + | {| | ||
|- | |- | ||
| + | | <span style="font-size:larger;">1. The addition of hyperbaric oxygen therapy improved the proportion of diabetic wounds that healed at one year.<br/> 2. The adverse event rate was low.</span> | ||
|} | |} | ||
| + | |||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Citation/s:'''</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Citation/s:'''</span> | ||
| − | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">1. Londahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care 2010;33(5):998-1003. </span> | + | |
| − | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">2. Londahl M, Katzman M, Nilsson A, Hammarlund C, Sellman A, Wykman A. Hugo-Persson M, Apelqvist J. A prospective study: hyperbaric oxygen therapy in diabetics with chronic foot ulcers. Journal of Wound Care 2006;10(15):457-459. </span> | + | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">1. Londahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care 2010;33(5):998-1003.</span> |
| − | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">3. Londahl M, Ladin-Olssen M, Katzman P. Hyperbaric oxygen therapy improves health-related quality of life in patients with diabetes and chronic foot ulcer. Diabetic Medicine 2011;28:186-190. </span> | + | |
| + | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">2. Londahl M, Katzman M, Nilsson A, Hammarlund C, Sellman A, Wykman A. Hugo-Persson M, Apelqvist J. A prospective study: hyperbaric oxygen therapy in diabetics with chronic foot ulcers. Journal of Wound Care 2006;10(15):457-459.</span> | ||
| + | |||
| + | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">3. Londahl M, Ladin-Olssen M, Katzman P. Hyperbaric oxygen therapy improves health-related quality of life in patients with diabetes and chronic foot ulcer. Diabetic Medicine 2011;28:186-190.</span> | ||
| + | |||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">4. Londahl M, Katzman P, Hammarlund C, Nilsson A, Landin-Olssen M. Relationship between ulcer healing after hyperbaric oxygen therapy and transcutaneous oximetry, toe blood pressure and ankle–brachial index in patients with diabetes and chronic foot ulcers. Diabetologia 2011;54:65-68.</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">4. Londahl M, Katzman P, Hammarlund C, Nilsson A, Landin-Olssen M. Relationship between ulcer healing after hyperbaric oxygen therapy and transcutaneous oximetry, toe blood pressure and ankle–brachial index in patients with diabetes and chronic foot ulcers. Diabetologia 2011;54:65-68.</span> | ||
| − | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Lead author's name and fax:''' Magnus Londahl [[mailto:magnus.londahl@med.lu.se | magnus.londahl@med.lu.se]] </span> | + | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">5. </span><span style="font-size:larger;">Londahl, M ; Fagher, K ; Nilsson, AL ; Katzman, P. Diabetologia, Improved 6-year survival in patients with chronic diabetic foot ulcers afterhyperbaric oxygen therapy: outcome from a randomised double-blind study. 2015 Sep, Vol.58 Suppl 1, pp.S31-S31</span> |
| + | |||
| + | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Lead author's name and fax:''' Magnus Londahl [[mailto:magnus.londahl@med.lu.se| magnus.londahl@med.lu.se]]</span> | ||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Three-part Clinical Question:''' For diabetic patients with chronic lower limb ulcers, does the additon of hyperbaric oxygenation to a specialised wound care protocol, result in an improved rate of healing?</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Three-part Clinical Question:''' For diabetic patients with chronic lower limb ulcers, does the additon of hyperbaric oxygenation to a specialised wound care protocol, result in an improved rate of healing?</span> | ||
| − | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Search Terms:''' Diabetes, chronic wound, skin ulcer </span> | + | |
| + | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Search Terms:''' Diabetes, chronic wound, skin ulcer</span> | ||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''The Study:'''Double-blinded concealed randomised controlled trial with intention-to-treat.</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''The Study:'''Double-blinded concealed randomised controlled trial with intention-to-treat.</span> | ||
| + | |||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''The Study Patients:''' Adult diabetic patients with ankle or foot ulcers for more than 3 months (including 2 months of specialised wound care) and where there is no major vessel disease requiring surgical intervention.</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''The Study Patients:''' Adult diabetic patients with ankle or foot ulcers for more than 3 months (including 2 months of specialised wound care) and where there is no major vessel disease requiring surgical intervention.</span> | ||
| − | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Control group''' (N = 45; 42 analysed): Specialised, comprehensive wound care plus 40 hyperbaric treatments breathing air at 2.5 ATA for 90 minutes daily Monday to Friday over 8 to 10 weeks. </span> | + | |
| + | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Control group''' (N = 45; 42 analysed): Specialised, comprehensive wound care plus 40 hyperbaric treatments breathing air at 2.5 ATA for 90 minutes daily Monday to Friday over 8 to 10 weeks.</span> | ||
| + | |||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Experimental group''' (N = 49; 48 analysed): As above, but breathed 100% oxygen at 2.5 ATA for 90 minutes daily on same schedule as the sham.</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Experimental group''' (N = 49; 48 analysed): As above, but breathed 100% oxygen at 2.5 ATA for 90 minutes daily on same schedule as the sham.</span> | ||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''The Evidence:'''</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''The Evidence:'''</span> | ||
| − | {| | + | |
| − | + | {| class="Table" style="border:solid windowtext 1.0pt" | |
|- | |- | ||
| − | | <span style'''" | + | | style="border:solid windowtext 1.0pt" | |
| + | <span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">Outcome</span></span></span>'''</span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">Time to Outcome</span></span></span>'''</span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">Sham rate</span></span></span>'''</span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">HBOT rate</span></span></span>'''</span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">Relative risk reduction</span></span></span>'''</span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">Absolute risk reductionN</span></span></span>'''</span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">NNT</span></span></span>'''</span> | ||
| + | |||
|- | |- | ||
| − | | | + | | style="border:solid windowtext 1.0pt" | |
| + | <span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">Wound healed</span></span></span>'''</span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">1 year</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">0.27</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">0.51</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">91%</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">-0.243</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">4</span></span></span></span> | ||
| + | |||
|- | |- | ||
| − | | | + | | style="border:solid windowtext 1.0pt; padding:.75pt .75pt .75pt .75pt" | |
| + | | style="border:solid windowtext 1.0pt; padding:.75pt .75pt .75pt .75pt" | | ||
| + | | style="border:solid windowtext 1.0pt; padding:.75pt .75pt .75pt .75pt" | | ||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">95% Confidence Intervals:</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">20% to 162%</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">.05 to 0.43</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">2 to 19</span></span></span></span> | ||
| + | |||
|- | |- | ||
| − | | | + | | style="border:solid windowtext 1.0pt" | |
| + | <span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">Death</span></span></span>'''</span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">1 year</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">0.07</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">0.02</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">70%</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">0.05</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">21</span></span></span></span> | ||
| + | |||
|- | |- | ||
| − | | | + | | style="border:solid windowtext 1.0pt; padding:.75pt .75pt .75pt .75pt" | |
| + | | style="border:solid windowtext 1.0pt; padding:.75pt .75pt .75pt .75pt" | | ||
| + | | style="border:solid windowtext 1.0pt; padding:.75pt .75pt .75pt .75pt" | | ||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">95% Confidence Intervals:</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">54% to 100%</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">0.04 to 0.13</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">NNT '''8 to INF NNH '''28 to INF</span></span></span></span> | ||
| + | |||
|- | |- | ||
| − | | | + | | style="border:solid windowtext 1.0pt" | |
| + | <span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">Major amputation</span></span></span>'''</span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">1 year</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">0.02</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">0.06</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">184%</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">-0.041</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">25</span></span></span></span> | ||
| + | |||
|- | |- | ||
| + | | style="border:solid windowtext 1.0pt; padding:.75pt .75pt .75pt .75pt" | | ||
| + | | style="border:solid windowtext 1.0pt; padding:.75pt .75pt .75pt .75pt" | | ||
| + | | style="border:solid windowtext 1.0pt; padding:.75pt .75pt .75pt .75pt" | | ||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">95% Confidence Intervals:</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">100% to 549%</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">0.04 to 1.21</span></span></span></span> | ||
| + | |||
| + | | style="border:solid windowtext 1.0pt" | | ||
| + | <span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" arial",sans-serif"=""><span style="color:#333333">NNT '''25 to INF NNH '''8 to INF</span></span></span></span> | ||
| + | |||
|} | |} | ||
| + | |||
| + | <span style="font-size:medium;">'''Kaplan-Meier survival over six years''' (Per-protocol analysis): Sham survival at six years 42% versus HBO group 68%, P = 0.026</span> | ||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Comments:'''</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Comments:'''</span> | ||
| + | |||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">1. Well conducted study with high methodological rigour and a low risk of bias.</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">1. Well conducted study with high methodological rigour and a low risk of bias.</span> | ||
| + | |||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">2. Quality of life was assessed at one year using the SF-36 questionnaire over eight dimensions. Those who received HBOT improved statistically significantly in two dimensions (physical functioning and emotional state), while those receiving sham had not significantly improved.</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">2. Quality of life was assessed at one year using the SF-36 questionnaire over eight dimensions. Those who received HBOT improved statistically significantly in two dimensions (physical functioning and emotional state), while those receiving sham had not significantly improved.</span> | ||
| + | |||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">3. Baseline transcutaneous oxygen levels correlated positively with the chance of healing in those who received HBOT. Neither toe blood pressures nor ankle-brachial index at baseline predicted healing.</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">3. Baseline transcutaneous oxygen levels correlated positively with the chance of healing in those who received HBOT. Neither toe blood pressures nor ankle-brachial index at baseline predicted healing.</span> | ||
| − | |||
| − | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Appraised by:''' Mike Bennett, POWH, Sydney; Thursday, 19 April 2012Email: [[mailto:m.bennett@unsw.edu.au | m.bennett@unsw.edu.au]] </span> | + | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">4. A per protocol analysis of those who received at least 35 treatment or sham sessions confirmed a benefit from HBOT (61% healing versus 27% healing at one year, P = 0.009).</span> |
| + | |||
| + | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Appraised by:''' Mike Bennett, POWH, Sydney; Thursday, 19 April 2012Email: [[mailto:m.bennett@unsw.edu.au| m.bennett@unsw.edu.au]]</span> | ||
<span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Kill or Update By:''' July 2021</span> | <span style="font-family: Arial,Helvetica,sans-serif; font-size: 120%;">'''Kill or Update By:''' July 2021</span> | ||
| − | + | | |
| − | [[File: | + | [[File:Sumhorsa.gif|center|Sumhorsa.gif]] |
| − | <span style="display: block; text-align: center;">'''<span style="color: #7c00ff; font-size: 26px;">[[Non- | + | <span style="display: block; text-align: center;">'''<span style="color: #7c00ff; font-size: 26px;">[[Non-healing_wounds|BACK]]</span>'''</span> |
Revision as of 22:24, 10 November 2019
The addition of hyperbaric oxygenation to a specialised wound care program for chronic diabetic foot ulcers resulted in improved survival, healing and quality of life.
Clinical bottom line:
| 1. The addition of hyperbaric oxygen therapy improved the proportion of diabetic wounds that healed at one year. 2. The adverse event rate was low. |
Citation/s:
1. Londahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care 2010;33(5):998-1003.
2. Londahl M, Katzman M, Nilsson A, Hammarlund C, Sellman A, Wykman A. Hugo-Persson M, Apelqvist J. A prospective study: hyperbaric oxygen therapy in diabetics with chronic foot ulcers. Journal of Wound Care 2006;10(15):457-459.
3. Londahl M, Ladin-Olssen M, Katzman P. Hyperbaric oxygen therapy improves health-related quality of life in patients with diabetes and chronic foot ulcer. Diabetic Medicine 2011;28:186-190.
4. Londahl M, Katzman P, Hammarlund C, Nilsson A, Landin-Olssen M. Relationship between ulcer healing after hyperbaric oxygen therapy and transcutaneous oximetry, toe blood pressure and ankle–brachial index in patients with diabetes and chronic foot ulcers. Diabetologia 2011;54:65-68.
5. Londahl, M ; Fagher, K ; Nilsson, AL ; Katzman, P. Diabetologia, Improved 6-year survival in patients with chronic diabetic foot ulcers afterhyperbaric oxygen therapy: outcome from a randomised double-blind study. 2015 Sep, Vol.58 Suppl 1, pp.S31-S31
Lead author's name and fax: Magnus Londahl [magnus.londahl@med.lu.se]
Three-part Clinical Question: For diabetic patients with chronic lower limb ulcers, does the additon of hyperbaric oxygenation to a specialised wound care protocol, result in an improved rate of healing?
Search Terms: Diabetes, chronic wound, skin ulcer
The Study:Double-blinded concealed randomised controlled trial with intention-to-treat.
The Study Patients: Adult diabetic patients with ankle or foot ulcers for more than 3 months (including 2 months of specialised wound care) and where there is no major vessel disease requiring surgical intervention.
Control group (N = 45; 42 analysed): Specialised, comprehensive wound care plus 40 hyperbaric treatments breathing air at 2.5 ATA for 90 minutes daily Monday to Friday over 8 to 10 weeks.
Experimental group (N = 49; 48 analysed): As above, but breathed 100% oxygen at 2.5 ATA for 90 minutes daily on same schedule as the sham.
The Evidence:
|
Outcome |
Time to Outcome |
Sham rate |
HBOT rate |
Relative risk reduction |
Absolute risk reductionN |
NNT |
|
Wound healed |
1 year |
0.27 |
0.51 |
91% |
-0.243 |
4 |
|
95% Confidence Intervals: |
20% to 162% |
.05 to 0.43 |
2 to 19 | |||
|
Death |
1 year |
0.07 |
0.02 |
70% |
0.05 |
21 |
|
95% Confidence Intervals: |
54% to 100% |
0.04 to 0.13 |
NNT 8 to INF NNH 28 to INF | |||
|
Major amputation |
1 year |
0.02 |
0.06 |
184% |
-0.041 |
25 |
|
95% Confidence Intervals: |
100% to 549% |
0.04 to 1.21 |
NNT 25 to INF NNH 8 to INF |
Kaplan-Meier survival over six years (Per-protocol analysis): Sham survival at six years 42% versus HBO group 68%, P = 0.026
Comments:
1. Well conducted study with high methodological rigour and a low risk of bias.
2. Quality of life was assessed at one year using the SF-36 questionnaire over eight dimensions. Those who received HBOT improved statistically significantly in two dimensions (physical functioning and emotional state), while those receiving sham had not significantly improved.
3. Baseline transcutaneous oxygen levels correlated positively with the chance of healing in those who received HBOT. Neither toe blood pressures nor ankle-brachial index at baseline predicted healing.
4. A per protocol analysis of those who received at least 35 treatment or sham sessions confirmed a benefit from HBOT (61% healing versus 27% healing at one year, P = 0.009).
Appraised by: Mike Bennett, POWH, Sydney; Thursday, 19 April 2012Email: [m.bennett@unsw.edu.au]
Kill or Update By: July 2021